A 13-year study involving nearly 100,000 participants found that the GLP-1 medication semaglutide is associated with a substantial decrease in hospitalizations and sick leave for people already diagnosed with depression or anxiety.
The research, published in The Lancet Psychiatry by an international team from Griffith University, the Karolinska Institutet and the University of Eastern Finland, tracked Swedish national registers between 2009 and 2022.
